TUNE-401 Epigenetic Silencing Clinical PoC

Summary Tune Therapeutics presented the first clinical proof-of-concept data for CRISPR-based epigenetic silencing in humans, demonstrating deep, dose-dependent and durable reductions in HBV biomarkers with TUNE-401 in chronic hepatitis B patients. What Happened At EASL 2026, Tune reported Phase 1b/2a data showing epigenetic silencing of…